EGFR and non-small cell lung carcinoma: Recent studies have revealed that inhibiting the glutamine transporter SLC1A5 can sensitize NSCLC cells to epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) and delay the acquisition of resistance (He et al., 2021; Pan et al., 2022).